Stock data
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK) reported revenue of US$184.42M and net income of -US$6.88M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$184.42M | — | -US$20.59M | -US$6.88M | — |
| 2024 | US$36.55M | — | -US$101.37M | -US$88.98M | — |
| 2023 | US$8.78M | — | -US$114.77M | -US$104.70M | — |
| 2022 | US$12.40M | — | -US$104.36M | -US$101.07M | — |
| 2021 | — | — | -US$86.06M | -US$85.81M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$9.32M | -US$61.62M | — |
| 2026-03-31 | US$6.23M | -US$50.00M | — |
| 2025-12-31 | US$1.40M | -US$57.93M | — |
| 2025-09-30 | US$10.63M | -US$38.35M | — |
| 2025-06-30 | US$13.82M | -US$23.48M | — |
| 2025-03-31 | US$158.57M | US$112.88M | — |
| 2024-12-31 | US$22.61M | -US$10.48M | — |
| 2024-09-30 | US$4.89M | -US$26.43M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.